ChromaTan Raises $2M Funding to Advance AAV Purification Technology

ChromaTan Receives $2M NIH IIB Grant

Key Highlights:

• Grant Funding: ChromaTan, a bioprocessing and biotools company, secured a $2 million grant from the National Institute of General Medical Sciences.
• Development of BioRMB™ Technology: The grant will be used to develop and integrate ChromaTan's BioRMB™ single-use, column-free, steady-state continuous counter-current elution technology for manufacturing AAVs.
• AAV Purification Process: The project aims to provide an AAV purification process for multiple serotypes, enhancing productivity, recovery, and product quality.

ChromaTan's Target Market

• Bioprocessing and Biomanufacturing: Companies involved in the production of biologics, including gene therapies, mRNA, and monoclonal antibodies.
• AAV Manufacturing: Organizations seeking advanced purification technologies for manufacturing adeno-associated viruses (AAVs).
• Research Institutions: Academic and research institutions involved in bioprocessing and biomanufacturing.

What ChromaTan Needs to Buy

• Research and Development Partnerships: Collaborations with research institutions and biotech companies to further develop and refine their BioRMB™ technology.
• Manufacturing Equipment and Supplies: Partnerships with suppliers of manufacturing equipment and single-use technologies for large-scale production.
• Commercial Partnerships: Collaborations with biopharmaceutical companies for the integration and adoption of ChromaTan's purification technology.